And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...
SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...
Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology ...
Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
Elanco Receives USDA Approval for Befrena (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis. News release. Elanco Animal Health. December 31, ...
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...
Nemolizumab is delivered via subcutaneous injection and was approved earlier this year for treating prurigo nodularis in adults. Two identical phase III trials -- ARCADIA 1 and ARCADIA 2-- supported ...
Skin condition flare-ups during the humid season are leading some individuals to avoid social events and celebrations.